Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to provide access to cabozantinib for eligible subjects with
medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by
the FDA and commercial availability of cabozantinib.